Mobile

An Open-label, International, Multi-Center, Phase I/II, Dose-escalation Trial Investigating the Safety of Zalutumumab, a Human Monoclonal Epidermal Growth Factor Receptor Antibody in Combination with ...

Update Il y a 4 ans
Reference: EUCTR2008-000781-23

An Open-label, International, Multi-Center, Phase I/II, Dose-escalation Trial Investigating the Safety of Zalutumumab, a Human Monoclonal Epidermal Growth Factor Receptor Antibody in Combination with Radiotherapy, in Patients with Stage III, IVa or IVb Locally Advanced Squamous Cell Carcinoma of the Head and Neck Ineligible for Platinum based Chemotherapy

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To evaluate the safety of repeat dosing and establish the maximum tolerated dose (MTD) of zalutumumab in combination with radiotherapy in patients with stage III, IVa or IVb locally advanced squamous cell carcinoma of the head and neck ineligible for platinum based chemotherapy

Inclusion criteria

  • Stage III, IVa or IVb Locally Advanced Squamous Cell Carcinoma of the Head and Neck Ineligible for Platinum based Chemotherapy

Links